Warhound Secures $200 Million to Build Genetically Engineered Military Canines

Two hundred million dollars has been raised to bring a new type of working dog to the U.S. military and emergency services. The funding round values Warhound at $1.2 billion and includes investment from Sequoia, 8VC, Corner Ventures, and In-Q-Tel. The latter is a venture firm supported by the CIA and other U.S. intelligence agencies. This launch marks the end of a stealth period for a venture that aims to solve a critical supply issue in defense logistics.

The core problem driving the initiative is a shrinking domestic pool of service animals. According to the company's launch announcement, more than 80% of working dogs used by the U.S. military currently come from Europe. Of those imported animals, fewer than half are deemed fit for service. This reliance on foreign sources creates a vulnerability in the supply chain for animals that perform dangerous tasks such as bomb detection and search operations. Warhound intends to localize and improve this supply through genetic engineering.

Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril conceived the project after meeting at a conference approximately a year ago. Luckey noted that more should be done to support the military's canine units. Lamm subsequently researched breeding practices and found that many dogs fail training due to inherited issues like poor eyesight, cancer risks, hip dysplasia, or muscle atrophy. The founders believe that engineering dogs with specific traits for health, longevity, and sensory capability can overcome these biological limitations.

The technical approach involves editing the genomes of top-performing breeds, specifically the Belgian Malinois and German Shepherd. The team has established a biobank using cell lines from these dogs. They plan to add genes that enhance performance and remove those associated with health problems. This process aims to create a new type of dog that is better suited for demanding missions. Colossal will license its technology to support this genetic work, while holding equity in the new business.

Anduril will provide the hardware and software components to assist the dogs and their handlers. This includes protection vests and goggles designed to improve situational awareness. Lamm described the concept as adding technology on top of the dog rather than inside it. For example, bulletproof vests could incorporate data sensors that transmit information back to handlers. This integration is intended to make the dogs safer and healthier, which in turn protects the human personnel working alongside them.

The timeline for deployment is aggressive. The first batch of dogs is currently being cloned and incubated. Births are expected in early 2027, with service ideally beginning within two years. Viagen, another company owned by Colossal, will handle the cloning process. Lamm noted that Viagen's technology has a high success rate, a track record Colossal already uses in its efforts to protect endangered species. The first animals will not exist until these cloning procedures are complete.

Warhound has not yet determined the price it will charge for these engineered animals. The company expects to sell to first responders, the Department of Defense, military service groups, and police forces. Lamm stated that the company has briefed various government groups about the business model. While the dogs will be genetically enhanced, Lamm assured that each animal will undergo the same training as any standard military working dog and will be managed by the purchasing agency.

To address concerns about animal welfare, the company is working under the guidance of the American Humane Society. This partnership aims to certify the training program for the new dogs. The founders also hope that when these military dogs retire, they will enter the Society's Military Working Dog Reunification Program. This program provides homes for retired service animals. The American Humane Society stated that it looks forward to working with Warhound and Colossal to ensure the animals are treated humanely, citing the organization's grounding in science and ethics.

The collaboration combines Colossal's expertise in gene editing and de-extinction efforts with Anduril's defense technology. Colossal is known for using AI to identify and copy animal genes, a skillset now applied to creating functional working dogs. Luckey serves as a partner in the venture but does not own equity in the company. The project represents a significant shift in how the U.S. prepares for future defense needs, blending biological innovation with advanced hardware to support the men and women in uniform.